Skip to content

Effect of amino acid mixture on blood glucose

Effect amino acid mixture on blood glucose - a randomized placebo controlled double blind cross-over study- - Effect amino acid mixture on blood glucose

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000056116
Enrollment
50
Registered
2024-11-15
Start date
2024-11-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults who feel they do not get enough physical activity

Interventions

amino acid mixture, single dose foods not containing amino acid mixture, single dose

Sponsors

KSO Corporation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)(Healthy) males and females aged between 20 to 64 years old. (2)Not heavy alcholic drinker(Subjects who can stop drinking from 2 days before each measurement) (3)Subjects who can make self-judgment and are voluntarily giving written concent form. (4)healthy adults who feel they do not get enough physical activity(less than 1 exercise/week)

Exclusion criteria

Exclusion criteria: (1)Subjects who use oral medication affecting blood glucose. (2)Subjects who constantly use supplements and/or functional foods (including Food for Specified Health Uses) affecting blood glucose. (3)Subjects who need medical treatment for diabetes. (4)Subjects who contract or are under treatment or are medical history for serious diseases (e.g.,liver disease, kidney disease, and/or heart disease), thyroid gland disease, adrenal gland disease, and/or metabolic disorder. (5)Subjects who have a operational history of digestive disease affecting digestion and absorption. (6)Subjects who are judged as unsuitable for the study based on the results of blood tests by the investigator at screening. (7)Subjects who have donated 400 mL of blood within 12 weeks prior to the start of the study and 200 mL of blood within 4 weeks and component blood donations (plasma component and platelet component blood donations) within 2 weeks prior to the start of the study. Also, considering the total amount of blood collected during the study, those who plan to donate blood within 12 weeks of the study. (8)Subjects who are diagnosed as anemic and not suitable for frequent collection of blood. (9)Subjects who developed diarrhea or took antibiotics within one week retroactive to the examination. (10)Subjects who are planning to participate in other clinical studies. (11)Subjects who are planning to become pregnant after informed consent for the current study or are pregnant or lactating. (12)Subjects who are judged as unsuitable for the study by the investigator for other reasons. (13) Glucose tolerance test (75 g OGTT): Fasting blood glucose level greater than 110 mg/dL, or 2-hour blood glucose level greater than 200 mg/dL (14) Glucose tolerance test (75 g OGTT): The blood glucose level does not rise at all. The behavior of the blood glucose level change is N-shaped or M-shaped.

Design outcomes

Primary

MeasureTime frame
Blood glucose levels

Secondary

MeasureTime frame
Insulin concentration Amino acid concentration

Countries

Japan

Contacts

Public ContactKyoko MIURA

Ajinomoto Co., Inc. Functional Ingredients Group Wellness Solution Development Center

kyouko.miura.jt9@asv.ajinomoto.com07043255184

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026